Natco Pharma announced that a US District Court has issued a decision in favour of Pharmacyclics (a subsidiary of AbbVie), the brand owner of Imbruvica in a PIV litigation involving the product.
NATCO and its marketing partner in US for the product, Alvogen Pine Brook LLC, USA, shall review the judgement and evaluate all options to appeal the judgement.
The company believes that it has a strong case and will continue to defend vigorously.
In the year 2018 NATCO and Alvogen, have filed an Abbreviated New Drug Application (ANDA) with PIV certification for generic version of the product.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.